



ONCOMINE COMPREHENSIVE FDA Approved Therapies

Non Small Cell Lung Cancer

Bio Marker

EGFR exon 19 deletions
& **EGFR** exon 21 L858R alterations

EGFR exon 20 T790M alterations

BRAF V600E

ROS1 Fusion

ALK Rearrangement

FDA-Approved Therapy

Gilotrif® (afatinib), **Iressa®** (gefitinib),
or **Tarceva®** (erlotinib)

Tagrisso® (osimertinib)

Tafinlar® (dabrafenib) in combination
with **Mekinist®** (trametinib)

Xalkori(crizotinib)

Alecensa® (alectinib), **Xalkori®** (crizotinib)
or **Zykadia®** (ceritinib)

Melanoma

Bio Marker

BRAF V600E

BRAF V600E or V600K

FDA-Approved Therapy

Tafinlar® (dabrafenib) or **Zelboraf®** (vemurafenib)

Mekinist® (trametinib) or **Cotellic®** (cobimetinib), in
combination with **Zelboraf®** (vemurafenib)

Breast Cancer

Bio Marker

PIK3CA alteration

ERBB2 (HER2) amplification

FDA-Approved Therapy

Piqray® (alpelisib)

Herceptin® (trastuzumab), **Kadcyla®** (ado-trastuzumab-
emtansine), or **Perjeta®** (pertuzumab)

Colorectal

Bio Marker

KRAS wild-type (absence of mutations in codons 12 &13)

KRAS wild-type (absence of mutations in exons 2, 3, and
4) and **NRAS** wild type (absence of mutations in exons 2, 3, and 4)

FDA-Approved Therapy

Erbitux® (cetuximab)

Vectibix® (panitumumab)

Bladder Cancer

Bio Marker

FGFR2 or **FGFR3** Fusion / alteration

FDA-Approved Therapy

Balversa® (erdafitinib)

Ovarian Cancer

Bio Marker

BRCA1/2 alterations

FDA-Approved Therapy

Rubraca® (rucaparib)

Pan Cancer (All Cancer Types)

Bio Marker

NTRK1, **NTRK2**, **NTRK3**

FDA-Approved Therapy

Vitrakvi® (larotrectinib)